- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03261531
Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity
January 14, 2020 updated by: Michael Camilleri, MD, Mayo Clinic
Effect of T6 Dermatome Electrical Stimulation on Gastric Motor Functions, Appetite, Satiation, Satiety and Weight Loss in Individuals With Overweight and Class I Obesity
Investigators are doing this research study to find out the effect of T6 dermatomal electrical stimulation (delivered by a Transcutaneous Electrical Nerve Stimulation (TENS) unit) on appetite and weight loss.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a Transcutaneous Electrical Nerve Stimulation (TENS) unit.
Participants will receive 15-minute T6 dermatome cutaneous stimulation with TENS unit applied immediately before ingestion of two of main meals of the day (breakfast and evening meal), and 60 minute stimulation applied immediately after ingestion of these meals.
Participants will apply the stimulus four times daily for a treatment period of at least 3 months.
Participants will keep a diary of weight once weekly and a weekly appetite record.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Overweight and obese adults (BMI ≥25 kg/m2 and ≤34.99 kg/m2) residing within 125 miles of Mayo Clinic in Rochester, Minnesota; these will be otherwise healthy individuals with no unstable psychiatric disease and not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, or endocrine (other than hyperglycemia on diet) disorders.
- Age: 18-65 years
- Gender: Men or women. Women of childbearing potential will be using an effective form of contraception, and have negative pregnancy tests within 48 hours of enrollment and before each radiation exposure.
- Subjects must have the ability to provide informed consent before any trial-related activities.
Eligible individuals will be asked to avoid taking additional medications and supplements for the duration of the study, unless reviewed and approved by the study team.
Exclusion Criteria:
- Abdominal surgery other than appendectomy, Caesarian section or tubal ligation
- Positive history of chronic gastrointestinal diseases, systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., Orlistat
- Positive history of diabetes mellitus or use of hypoglycemic medications
- Positive history of spinal cord injury and/or chronic back pain
- Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD) (12), a self-administered alcoholism screening test (AUDIT-C) (13), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) (14). If such a dysfunction is identified by a HAD score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
- Intake of medication, whether prescribed or over the counter (except multivitamins), within 7 days of the study. Exceptions are birth control pill, estrogen replacement therapy, thyroxine replacement therapy, low dose analgesia or anti-inflammatory medications (Acetaminophen and Ibuprofen) and any medication administered for co-morbidities as long as they do not alter gastrointestinal motility including gastric emptying and gastric accommodation.
- Subjects may also be excluded from participation for other factors at the discretion of the principal investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transcutaneous electrical nerve stimulation (TENS)
Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
|
Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Weight
Time Frame: Baseline, 3 months
|
Change in body weight will be measured in kilograms or pounds
|
Baseline, 3 months
|
Gastric Half-emptying Time (GE T 1/2)
Time Frame: After 1 day treatment (approximately at 4 hours)
|
The time for half of the ingested solids to leave the stomach
|
After 1 day treatment (approximately at 4 hours)
|
Gastric Half-emptying Time (GE T 1/2)
Time Frame: At 3 months, approximately 2 hours after radiolabeled meal is ingested
|
The time for half of the ingested solids to leave the stomach
|
At 3 months, approximately 2 hours after radiolabeled meal is ingested
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Gastric Volume by 99mTc-SPECT Imaging
Time Frame: At 3 months, approx 20 minutes after 99mTC injection
|
A noninvasive SPECT method will be used to measure gastric volume.
Subjects will report to the clinic after an overnight fast.
The first fasting scan will be obtained, and the study medication (99mTc) will be given subcutaneously.
After 10 min, a 2nd fasting post medication scan will be obtained.
Each scan requires about 9-12 min.
Tomographic images of the gastric wall will be obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body.
This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content.
Volume will be measured in mL.
|
At 3 months, approx 20 minutes after 99mTC injection
|
Postprandial Gastric Volume (Gastric Accommodation) by 99mTc-SPECT Imaging
Time Frame: At 3 months, approximately 30 min after liquid meal
|
A noninvasive SPECT method will be used to measure gastric volume after a liquid nutritional supplement meal.
Subjects reported to the clinic after an overnight fast.
99mTC will be given by an intravenous injection in the forearm.
The first fasting scan was obtained, and the study medication (99mTc) will be given subcutaneously.
After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans will be obtained.
Each scan requires about 9-12 min.
Tomographic images of the gastric wall will be obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body.
This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content.
Volume will be measured in mL.
|
At 3 months, approximately 30 min after liquid meal
|
Change in Gastric Emptying Percentage
Time Frame: Day 1, 3 months
|
The time for gastric retention of ingested solids or liquid to leave the stomach, measured in percentage.
|
Day 1, 3 months
|
Satiation Volume (Level 3)
Time Frame: Approximately 30 minutes after the liquid meal
|
Subjects will ingest a liquid nutrient drink at a rate of 120 mL every 4 minutes; the volume ingested at each level of fullness will be recorded.
Participants record their sensations of fullness using a numerical scale from 0 to 5, with level 0 being no symptoms, level 3 corresponding to fullness sensation after a typical meal ("volume to fullness"), and level 5 corresponding to the maximum tolerated volume (MTV).
Nutrient intake is stopped when subjects reach the score of 5.
|
Approximately 30 minutes after the liquid meal
|
Satiation Maximum Tolerated Volume (Level 5)
Time Frame: Approximately 30 minutes after the liquid meal
|
Subjects will ingest a liquid nutrient drink at a rate of 120 mL every 4 minutes; the volume ingested at each level of fullness will be recorded.
Participants record their sensations of fullness using a numerical scale from 0 to 5, with level 0 being no symptoms, level 3 corresponding to fullness sensation after a typical meal ("volume to fullness"), and level 5 corresponding to the maximum tolerated volume (MTV).
Nutrient intake is stopped when subjects reach the score of 5.
|
Approximately 30 minutes after the liquid meal
|
Mean Kcal Intake at Buffet Meal as a Measure of Appetite
Time Frame: At 3 months, approximately 30 minutes after the buffet meal
|
Assessment of kcal intake as a measure of appetite buffet meal to measure total caloric intake.
5 hours after ingesting 300 mL liquid nutrient as part of the gastric volume study, participants will be invited to eat, during a 30-minute period, a standard "free feeding" meal.
The total amount of food consumed will be analyzed by the study dietitian.
|
At 3 months, approximately 30 minutes after the buffet meal
|
Change in Appetite Score
Time Frame: Baseline, 3 months
|
Ratings of appetite will be measured every 30 minutes between the time of ingestion of standard liquid breakfast and the start of the ad libitum meal.
The appetite rating will be measured by 4- 100 mm long Visual Analog Scales (VAS).
The VAS does not have any pre-set marks between the extremes of 0 for negative rating and 100 mm for positive rating.
The investigator measures the mark made by the participant in mm and records this for the value.
The overall appetite score will be calculated as the average of the four individual scores (satiety + fullness+100-prospective food consumption + hunger/4.
|
Baseline, 3 months
|
Change in Fasting and Peak Postprandial Plasma Ghrelin at 3 Months
Time Frame: baseline, 90 minutes postprandially
|
Total ghrelin will be measured by a radioimmunoassay technique.
|
baseline, 90 minutes postprandially
|
Change in Fasting and Peak Postprandial Glucagon-like Peptide-1 (GLP-1) at 3 Months
Time Frame: baseline, 90 minutes postprandially
|
Glucagon-like peptide-1 (GLP-1) will be measured by a radioimmunoassay technique.
|
baseline, 90 minutes postprandially
|
Change in Fasting and Peak Postprandial Peptide Tyrosine Tyrosine (PYY) at 3 Months
Time Frame: baseline, 90 minutes postprandially
|
Peptide Tyrosine Tyrosine (PYY) will be measured by radioimmunoassay.
|
baseline, 90 minutes postprandially
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Camilleri, M.D, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 21, 2017
Primary Completion (Actual)
January 30, 2019
Study Completion (Actual)
January 30, 2019
Study Registration Dates
First Submitted
August 8, 2017
First Submitted That Met QC Criteria
August 22, 2017
First Posted (Actual)
August 25, 2017
Study Record Updates
Last Update Posted (Actual)
February 5, 2020
Last Update Submitted That Met QC Criteria
January 14, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-001916
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Transcutaneous electrical nerve stimulation (TENS)
-
University Hospital, ToulouseMinistry of Health, FranceTerminatedPeripheral Artery DiseaseFrance
-
Karolinska University HospitalActive, not recruitingHip Fractures | Hip Osteoarthritis | Orthopedic Disorder | Post Operative PainSweden
-
Hawra Al-DandanRecruitingOveractive Bladder SyndromeSaudi Arabia
-
Institut Cancerologie de l'OuestTerminated
-
Tufts Medical CenterNot yet recruitingAnalgesia | Pain, Acute | Patient Preference | IUDUnited States
-
Fatih Sultan Mehmet Training and Research HospitalCompleted
-
Hawaii Pacific HealthUnknownAnalgesia | Cesarean Section | Transcutaneous Electric Nerve StimulationUnited States
-
European University of LefkeCompletedLateral Epicondylitis (Tennis Elbow) Bilateral | Pain in Arm, Unspecified | Tenosynovitis Elbow
-
Hospital of South West JutlandTerminated
-
University of Campinas, BrazilCompletedEndometriosisBrazil